Oric

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. The company's resistance platform targets three mechanisms: innate resistance (unaddressed oncogenic drivers), acquired resistance (induced or enriched oncogenic drivers arising in response to treatment), and bypass resistance (compensatory signaling pathways activated in response to treatment). ORIC's lead programs include rinzimetostat (ORIC-944), a PRC2 inhibitor in Phase 1b combination studies in metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant EGFR/HER2 inhibitor in Phase 1b studies across multiple NSCLC patient populations including EGFR exon 20 and PACC mutations. The company is headquartered in South San Francisco, California and is publicly traded on Nasdaq.